Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 5/20 | 0.41 |
| ▸ | IL2 | P60568 | 5/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16021241 | 0.95 | ALDH1A1 (0.45) | FOLH1ALDH1A1LCKALBIL2 | |
| SCHEMBL16021248 | 0.95 | FOLH1 (0.47) | FOLH1ALDH1A1LCKALBIL2 | |
| SCHEMBL13938296 | 0.94 | ALDH1A1 (0.46) | FOLH1ALDH1A1EGFRPOLB | |
| SCHEMBL14137770 | 0.87 | FOLH1 (0.51) | FOLH1ALDH1A1LCKALBIL2 | |
| SCHEMBL13346550 | 0.86 | FOLH1 (0.47) | FOLH1LCKALBIL2POLB | |
| SCHEMBL31072235 | 0.85 | ALDH1A1 (0.48) | ALDH1A1POLB | |
| SCHEMBL13123764 | 0.85 | ALDH1A1 (0.48) | ALDH1A1POLB | |
| SCHEMBL15943457 | 0.83 | LCK (0.49) | FOLH1ALDH1A1LCKHDAC1HDAC6 | |
| SCHEMBL23864850 | 0.82 | ALDH1A1 (0.47) | ALDH1A1EGFRPOLB | |
| SCHEMBL24091032 | 0.82 | ALDH1A1 (0.46) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770465-B2 | Inherently radiopaque polymeric products for embolotherapy | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20140255335-A1 | INHERENTLY RADIOPAQUE POLYMERIC PRODUCTS FOR EMBOLOTHERAPY | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140255335-A1 | INHERENTLY RADIOPAQUE POLYMERIC PRODUCTS FOR EMBOLOTHERAPY | CD47, FGB, ELANE | FOLH1 293/4885ALDH1A1 3266/4885LCK 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.